Ixensor Co

Ixensor Co EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Ixensor Co (6734.TWO) as of Nov 5, 2026 is -66.28 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -61.76 % — a change of 7.31% (lower).

EBIT/Assets

-66.28 %

YoY

7.31%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Ixensor Co is 2025 -66.28 % . Operating Income to Assets Ratio (EBIT/Assets) of Ixensor Co was 2024 -61.76 % . It decreases by 7.31% lower compared to the previous year.

The Ixensor Co EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
-42.21 TWD
Jan 1, 2019
-60.80 TWD
Jan 1, 2020
-82.12 TWD
Jan 1, 2021
-110.74 TWD
Jan 1, 2022
-5.00 TWD
Jan 1, 2023
-65.40 TWD
Jan 1, 2024
-61.76 TWD
Jan 1, 2025
-66.28 TWD
The Ixensor Co EBIT/Assets history
YEAREBIT/AssetsYoY
-66.28 %+7.31%
-61.76 %-5.57%
-65.40 %+1,209.10%
-5.00 %-95.49%
-110.74 %+34.85%
-82.12 %+35.07%
-60.80 %+44.02%
-42.21 %-37.25%
-67.27 %+68.99%
-39.81 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ixensor Co Stock analysis

What does Ixensor Co do? iXensor Co., Ltd. generates revenue through its PixoTest Blood Glucose Monitoring System and ovulation detection system, targeting individuals managing diabetes and reproductive health. The company's technology platform measures biochemical parameters including blood sugar, luteinizing hormone, and cholesterol, providing data for diabetes management services. Its integrated medical device solutions serve customers seeking self-monitoring tools for chronic conditions and fertility tracking. The firm's products are designed for direct consumer use, with the PixoTest system offering blood glucose monitoring and the ovulation detection system supporting female hormone cycle management. These solutions leverage the company's platform to deliver personalized health insights without requiring third-party partnerships. The target segments include patients with diabetes and individuals tracking fertility cycles through biochemical monitoring. Ixensor Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ixensor Co stock

Operating Income to Assets Ratio (EBIT/Assets) of Ixensor Co is -66.28 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Ixensor Co changed from -61.76 % to -66.28 %, representing a 7.31% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Ixensor Co since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Ixensor Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Ixensor Co

All Key Metrics — Ixensor Co